FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2186536638> ?p ?o ?g. }

• W2186536638 endingPage "411" @default.
• W2186536638 startingPage "403" @default.
• W2186536638 abstract "We and others have demonstrated the antineoplastic efficacy of paclitaxel as a single agent in metastatic breast cancer. We performed this phase I trial to evaluate the combination of paclitaxel with doxorubicin.Eligible patients had measurable or evaluable metastatic breast cancer for which this was the initial cytotoxic treatment. They may have received adjuvant chemotherapy with other drugs. The study had four parts. In part 1, the patients received paclitaxel by 24-hour infusion followed by doxorubicin by 48-hour infusion. The paclitaxel dose was to be escalated from a starting dose of 125 mg/m2, and the doxorubicin dose was to remain constant at 60 mg/m2 with treatment repeated every three weeks. The results of part 1 prompted part 2 which was a study of the reverse sequence. Part 3 was a formal study of pharmacology and has been reported (J Clin Oncol 14: 2713-21, 1996). In part 4, patients received doxorubicin 50 mg/m2 by bolus followed by paclitaxel 150 mg/m2 by 24-hour infusion for courses 1 and 2. In all subsequent courses doxorubicin was administered by 48-hour infusion. All patients in all four parts of the study had baseline cardiac scans. All patients received standard premedication for paclitaxel.Forty-eight patients were treated in all four parts of the study. In part 1 (10 patients), the maximum tolerated dose (MTD) was paclitaxel 125 mg/m2/24 hours followed by doxorubicin 48 mg/m2/48 hours as defined by dose-limiting mucositis and neutropenic fever which occurred at the starting dose. For part 2 (21 patients), the MTD was doxorubicin 60 mg/m2/48 hours followed by paclitaxel 160 mg/m2/24 hours. In part 4 (seven patients), the MTD was doxorubicin 50 mg/m2/bolus followed by paclitaxel 135 mg/m2/24 hours. In parts 2 and 4, the dose-limiting toxic effect was neutropenia. Of the entire cohort of 48 patients, seven (15%) had a complete response (one persists at five years without intervening therapy), 26 (54%) had a partial response for an objective response rate of 69% (95% confidence interval (95% CI): 54%-81%). The median follow-up of all living patients is 38+ months (range 20+ to 62+); the median response duration is seven months (range 2-33.7+); the median overall survival is 20.5 months (range 5-54+). The median time to progression is 9.6 months (range 1-33.7+ months). Two patients developed congestive heart failure, one at 24 months after her final dose of doxorubicin which amounted to a cumulative lifetime total doxorubicin dose of 870 mg/m2, one after a total of 660 mg/m2. In both, cardiac symptoms were controlled with medications.The combination of paclitaxel/24 hours with doxorubicin/48 hours is an effective antineoplastic treatment for metastatic breast cancer. However, the incidence of complete response, the median overall survival, and time to progression were not greater than for standard doxorubicin-based combinations. Additionally, a sequence-dependent interaction between paclitaxel and doxorubicin, given in the schedule described here, was defined. Other strategies and schedules should be evaluated to maximize the antineoplastic efficacy of these two potent agents." @default.
• W2186536638 created "2016-06-24" @default.
• W2186536638 creator A5023018104 @default.
• W2186536638 creator A5026926354 @default.
• W2186536638 creator A5027653267 @default.
• W2186536638 creator A5028916394 @default.
• W2186536638 creator A5029774182 @default.
• W2186536638 creator A5030497065 @default.
• W2186536638 creator A5031531962 @default.
• W2186536638 creator A5045860204 @default.
• W2186536638 creator A5049208967 @default.
• W2186536638 creator A5063132073 @default.
• W2186536638 creator A5080151010 @default.
• W2186536638 creator A5080832682 @default.
• W2186536638 date "1999-04-01" @default.
• W2186536638 modified "2023-09-27" @default.
• W2186536638 title "Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: Phase I results" @default.
• W2186536638 cites W1753106810 @default.
• W2186536638 cites W1960713055 @default.
• W2186536638 cites W1996285570 @default.
• W2186536638 cites W2007353700 @default.
• W2186536638 cites W2008766841 @default.
• W2186536638 cites W2014867268 @default.
• W2186536638 cites W2017120938 @default.
• W2186536638 cites W2032602077 @default.
• W2186536638 cites W2060242711 @default.
• W2186536638 cites W2064367468 @default.
• W2186536638 cites W2133003338 @default.
• W2186536638 cites W2133243551 @default.
• W2186536638 cites W2148700329 @default.
• W2186536638 cites W2227235589 @default.
• W2186536638 cites W2232368099 @default.
• W2186536638 cites W2242824667 @default.
• W2186536638 cites W4255152173 @default.
• W2186536638 cites W4255483444 @default.
• W2186536638 cites W4293241248 @default.
• W2186536638 doi "https://doi.org/10.1023/a:1008360406322" @default.
• W2186536638 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10370782" @default.
• W2186536638 hasPublicationYear "1999" @default.
• W2186536638 type Work @default.
• W2186536638 sameAs 2186536638 @default.
• W2186536638 citedByCount "20" @default.
• W2186536638 countsByYear W21865366382016 @default.
• W2186536638 countsByYear W21865366382019 @default.
• W2186536638 countsByYear W21865366382020 @default.
• W2186536638 countsByYear W21865366382022 @default.
• W2186536638 crossrefType "journal-article" @default.
• W2186536638 hasAuthorship W2186536638A5023018104 @default.
• W2186536638 hasAuthorship W2186536638A5026926354 @default.
• W2186536638 hasAuthorship W2186536638A5027653267 @default.
• W2186536638 hasAuthorship W2186536638A5028916394 @default.
• W2186536638 hasAuthorship W2186536638A5029774182 @default.
• W2186536638 hasAuthorship W2186536638A5030497065 @default.
• W2186536638 hasAuthorship W2186536638A5031531962 @default.
• W2186536638 hasAuthorship W2186536638A5045860204 @default.
• W2186536638 hasAuthorship W2186536638A5049208967 @default.
• W2186536638 hasAuthorship W2186536638A5063132073 @default.
• W2186536638 hasAuthorship W2186536638A5080151010 @default.
• W2186536638 hasAuthorship W2186536638A5080832682 @default.
• W2186536638 hasBestOaLocation W21865366381 @default.
• W2186536638 hasConcept C121608353 @default.
• W2186536638 hasConcept C126322002 @default.
• W2186536638 hasConcept C126894567 @default.
• W2186536638 hasConcept C141071460 @default.
• W2186536638 hasConcept C2775930923 @default.
• W2186536638 hasConcept C2776694085 @default.
• W2186536638 hasConcept C2777063308 @default.
• W2186536638 hasConcept C2777292972 @default.
• W2186536638 hasConcept C2778300832 @default.
• W2186536638 hasConcept C2778496288 @default.
• W2186536638 hasConcept C2781303535 @default.
• W2186536638 hasConcept C2781413609 @default.
• W2186536638 hasConcept C42219234 @default.
• W2186536638 hasConcept C43376680 @default.
• W2186536638 hasConcept C530470458 @default.
• W2186536638 hasConcept C71924100 @default.
• W2186536638 hasConceptScore W2186536638C121608353 @default.
• W2186536638 hasConceptScore W2186536638C126322002 @default.
• W2186536638 hasConceptScore W2186536638C126894567 @default.
• W2186536638 hasConceptScore W2186536638C141071460 @default.
• W2186536638 hasConceptScore W2186536638C2775930923 @default.
• W2186536638 hasConceptScore W2186536638C2776694085 @default.
• W2186536638 hasConceptScore W2186536638C2777063308 @default.
• W2186536638 hasConceptScore W2186536638C2777292972 @default.
• W2186536638 hasConceptScore W2186536638C2778300832 @default.
• W2186536638 hasConceptScore W2186536638C2778496288 @default.
• W2186536638 hasConceptScore W2186536638C2781303535 @default.
• W2186536638 hasConceptScore W2186536638C2781413609 @default.
• W2186536638 hasConceptScore W2186536638C42219234 @default.
• W2186536638 hasConceptScore W2186536638C43376680 @default.
• W2186536638 hasConceptScore W2186536638C530470458 @default.
• W2186536638 hasConceptScore W2186536638C71924100 @default.
• W2186536638 hasIssue "4" @default.
• W2186536638 hasLocation W21865366381 @default.
• W2186536638 hasLocation W21865366382 @default.
• W2186536638 hasOpenAccess W2186536638 @default.
• W2186536638 hasPrimaryLocation W21865366381 @default.
• W2186536638 hasRelatedWork W131577465 @default.

• next